Effect Of Empagliflozin In Chronic Kidney Disease Patients: An Observational Study

Chronic kidney disease (CKD) is often progressive, with decreased glomerular filtration rate (GFR) and presence of albuminuria. These are the key risk factors for further deterioration of kidney functions resulting in kidney failure. Slowing CKD progression and prolonging the need for dialysis or a kidney transplant will help in improving the quality of life, decrease the cardiovascular morbidity and mortality, and also cost of kidney replacement therapy. This study aims to evaluate the effect of Empagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on patients with chronic kidney disease (CKD). The primary objectives are to assess changes in eGFR, Blood Urea, Serum Creatinine, and urine albumin-creatinine ratio, as well as to monitor adverse effects using the WHO causality assessment scale. This study is a prospective observational study conducted at the Medicine and Nephrology Department of R.L. Jalappa Hospital, Kolar, over a period of one and a half years. The study will include 65 CKD patients receiving Empagliflozin, with assessments at baseline, three months, and six months. Various randomized controlled trials (RCTs) have shown favorable outcomes with Empagliflozin in reducing the risk of kidney disease progression and cardiovascular death. This study aims to fill the gap in real-world clinical practice data and provide insights into the efficacy, safety, and tolerability of Empagliflozin among CKD patients.